Zai Lab (09688) rose more than 4% in the afternoon, according to the Zhì tōng cáijīng APP. As of press time, it rose 3.64% to HKD 14.24, with a turnover of HKD 29.885 million.

Zai Lab announced at noon that the National Medical Products Administration has approved the production license application of Vilog ™ (Eliglucoside Aga Mogam). The biological product is used in combination with conventional therapeutic drugs for the treatment of adult generalized myasthenia gravis (gMG) patients who test positive for acetylcholine receptor (AChR) antibodies.

Prior to this, CMB International pointed out that the growth of Aga Mogam is becoming increasingly strong, maintaining its annual sales guidance of 70 million US dollars. The bank stated that with sustained volume and expansion of indications, Aga Mogam is expected to provide a strong driving force for Zai Lab to achieve its strategic goal (compound annual revenue growth rate exceeding 50% from 2023 to 2028).